Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. FDX
2. CBRS
3. KBH
4. HON
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. USO

Go back to Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data

Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

January 5, 2016 4:05 PM EST

- Consistent Treatment Effect Observed on Biomarkers in Overall Patient Population -

- Emricasan Improves Key Measures of Liver Function in High Medical Need Subgroup -

- Conference Call and Webcast Presentation at... More